Nucleolin (NCL) has a functional role in cancer regulation. Targeting surface NCL impaired the progression of several cancer cell types in vitro and in vivo. The present up‑to‑date review provides data to support the notion of targeting NCL among the developing anticancer approaches, including the use of anti‑NCL peptides, aptamers, anti‑NCL antibodies/pseudopeptides and NCL‑specific T‑cells. The NCL‑specific T‑cells generated by antigen presenting cells or NCL peptides illustrate the use of the platforms that open a window for using immunotherapy targeted at NCL as another very promising approach in NCL‑positive cancers. |
เงินทุน
- New Researcher Grant, Mahidol University (grant no. R016420006)
- Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University (grant no. R016334002)
- Research Grant, National Research Council of Thailand, and Mid‑Research Grant (N42A650343)
- National Research Council of Thailand and Mahidol University (grant no. R016541043)
กระดาษต้นฉบับ
ชื่อบทความต้นฉบับ: Nucleolin-based targeting strategies in cancer treatment: Focus on cancer immunotherapy
วารสาร: Int J Mol Med
ดอย: 10.3892/ijmm.2023.5284